Trade ICU Medical Inc - ICUI CFD

Trading Conditions

• TypeThis financial market is available for CFD trading.Learn more about:CFDs: CFD
• Spread: 0.21
• Long position overnight funding adjustmentLong position overnight funding adjustmentMargin. Your investment$1,000.00Overnight funding adjustmentCharges from full value of position-0.021485 %(-$4.30)Trade size with leverage ~ $20,000.00Money from leverage ~ $$19,000.00Go to platform: -0.02149%
• Short position overnight funding adjustmentShort position overnight funding adjustmentMargin. Your investment$1,000.00Overnight funding adjustmentCharges from full value of position-0.000738 %(-$0.15)Trade size with leverage ~ $20,000.00Money from leverage ~ $$19,000.00Go to platform: -0.00074%
• Overnight funding adjustment time: 21:00 (UTC)
• Currency: USD
• Min traded quantity: 0.1
• Margin: 5.00%
• Stock exchange: United States of America
• Commission on trade: 0%
• Guaranteed stop premiumA guaranteed stop-loss (GSL) fee is only charged if the GSL is triggered. Please consult the Charges and Fees section of our website for more details.: 1%

• Margin. Your investment: $1,000.00
• Overnight funding adjustmentCharges from full value of position: -0.021485 %
  (-$4.30)

• Margin. Your investment: $1,000.00
• Overnight funding adjustmentCharges from full value of position: -0.000738 %
  (-$0.15)

Key Stats

• Prev. Close: 184.26
• Open: 182.76
• 1-Year Change: 62.41%
• Day's Range: 180.95 - 185.34

Trade ICU Medical Inc - ICUI

About ICU Medical Inc

ICU Medical, Inc. (ICU) is engaged in the development, manufacturing and sale of medical products used in infusion therapy and critical care applications. The Company’s product portfolio includes IV solutions, IV smart pumps with pain management and safety software technology, dedicated and non-dedicated IV sets and needlefree connectors designed to help meet clinical, safety and workflow goals. Its critical care products help clinicians get real-time access to patients’ hemodynamic and cardiac status with a portfolio of monitoring systems and advanced sensors and catheters. Its primary critical care products include Cogent, CardioFlo, TDQ and OptiQ, TriOx, Transpac and SafeSet. It sells its products through its direct sales force and through independent distributors. Its IV Solutions products include IV Therapy and Diluents, and Irrigation. Its Infusion System products include Infusion Pump Hardware, IV Mediation Safety Software and Professional Services.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, ICU Medical Inc revenues increased 4% to $1.32B. Net income increased 19% to $103.1M. Revenues reflect Infusion Consumables segment increase of 17% to $555.2M, Critical Care segment increase of 1% to $49.3M, United States segment increase of 3% to $941.8M, EMEA segment increase of 11% to $147.5M. Net income benefited from Restructuring Charges/Provisions decrease of 37% to $18M (expense).

Equity composition

Common Stock $.10 Par, 03/11, 80M auth., 14,855,000 issd., less 1,123,000 shs. in Treas @ $38.95M. Insiders & Strategic holders own 11.33%. IPO 3/92, 1.3M shares @ $11.00 by Sutro& Co., Inc. PO 7/95, 2.07M shares @ $12 by Rodman & Renshaw, Inc. 3/02, 4/93, 3-for-2 stock splits. FY'03 Q4 are being restated.